![]() |
市場調查報告書
商品編碼
2096351
全球質譜市場(至 2031 年):按產品類型、進樣口類型(LC-MS、GC-MS、ICP-MS、其他)、應用(體學、藥物發現、食品、環境)和最終用戶(製藥、生物技術)分類Mass Spectrometry Market by Product, Inlet Type (LC-MS, GC-MS, ICP-MS, Other Inlet Types), Application (Omics, Drug Discovery, Food, Environmental), End User (Pharma, Biotech) - Global Forecast to 2031 |
||||||
全球質譜市場預計將從 2026 年的 70.74 億美元成長到 2031 年的 107.833 億美元,2026 年至 2031 年的複合年成長率為 8.8%。
| 調查範圍 | |
|---|---|
| 調查期 | 2026-2031 |
| 基準年 | 2025 |
| 預測期 | 2026-2031 |
| 單元 | 金額(美元) |
| 部分 | 產品、進料口類型、應用程式、最終用戶、地區 |
| 目標區域 | 北美、歐洲、亞太地區、拉丁美洲、中東和非洲 |
全球質譜市場正經歷強勁成長,這主要得益於精準醫療、生技藥品開發、多體學研究以及監管主導的生物分析檢測在製藥、生物技術、臨床診斷、食品安全和環境等領域的快速發展。推動市場成長的最新趨勢之一是高解析度液相層析-串聯質譜(LC-MS/MS)和混合質譜平台的日益普及。這些平台整合了人工智慧分析、自動化、雲端連接的實驗室工作流程和機器人樣品製備等技術,從而提高了通量、重現性和操作效率。

製藥和生物製藥公司正大力投資先進的質譜系統,用於生物標記發現、抗體藥物複合體(ADC) 表徵、細胞和基因治療開發以及符合 FDA 標準的藥物動力學分析。同時,醫院和診斷實驗室也擴大採用桌上型臨床液相層析串聯質譜 (LC-MS/MS) 系統進行內分泌學、毒理學和精準腫瘤學檢測。此外,透過合約研究組織 (CRO) 提供的生物分析服務的快速擴張、全氟烷基和多氟烷基物質 (PFAS) 及環境污染物檢測的增加,以及向數位化整合和標準化分析生態系統的轉變,都進一步推動了全球對下一代混合型和高通量質譜平台的需求。
儀器設備部分在質譜市場中佔最大佔有率。
按產品細分市場來看,預計在預測期內,儀器細分市場將佔據最大佔有率,這主要得益於製藥、生物技術、臨床研究和多組體學應用領域對先進分析技術投資的增加。藥物研發流程日益複雜,尤其是在生物製藥、抗體藥物複合體(ADC)、細胞和基因治療以及精準醫療等領域,推動了對高性能質譜儀需求的成長。製藥和生物製藥公司正在增加對新一代質譜平台的投資,這些平台具有更高的靈敏度、更高解析度的分析能力、自動化程度以及人工智慧驅動的工作流程功能,旨在提高生物分析效率、縮短研究週期並確保符合監管要求。此外,在北美和歐洲等已開發地區,持續的技術創新以及研究實驗室、醫院和臨床機構對高通量分析系統的日益普及,正在加速儀器的更換和升級週期。
液相層析質譜聯用技術在質譜市場中佔據最大佔有率。
按進樣口類型分類,液相層析質譜聯用(LC-MS)預計將在預測期內引領全球質譜市場的發展,這主要得益於其在製藥、生物技術、臨床診斷、食品安全和環境檢測等領域的廣泛應用。 LC-MS是目前應用最廣泛的分析技術之一,能夠對複雜的生物和化學化合物進行高靈敏度和高精度的鑑定和定量。由於法規核准的增加、生技藥品藥物管理局(FDA)和其他國際監管機構發布了ICH M10生物分析方法驗證指南。這些指南認可LC-MS/MS是藥物動力學分析、生物標記定量和受監管藥物檢測的首選技術。這項監管轉變正促使製藥公司和合約研究組織(CRO)加強對新一代LC-MS/MS平台的投資,以支持臨床開發、法規遵循和高通量藥物分析。
預計亞太地區將呈現最高的市場成長率。
亞太地區的質譜市場正經歷快速轉型,這主要得益於中國、印度、日本、韓國和東南亞等地生物製藥生產、多體學研究、精準醫療項目以及大規模製藥外包業務的蓬勃發展。最新趨勢之一是,合約研究機構 (CRO)、合約研發生產機構 (CDMO) 和生物製藥生產設施擴大採用高解析度混合液相色譜-串聯質譜 (LC-MS/MS)、Orbitrap 和四極桿飛行時間質譜 (Q-TOF) 系統,用於先進的生物製藥表徵、雜質分析、糖基化分析以及細胞和基因治療工作流程。該地區各國政府正大力投資基因組學、蛋白質組學、代謝體學和轉化醫學項目,加速人工智慧賦能、雲連結的質譜平台在科學研究和臨床診斷領域的應用。該地區另一項重大變革趨勢是分析實驗室的快速數位化,這體現在機器人樣品製備、實驗室資訊系統 (LIS) 整合以及自動化生物分析工作流程等方面,旨在支援高通量藥物發現和法規遵循。此外,亞太地區正崛起為全球醫藥和生物分析外包中心,這為合約研究機構 (CRO) 和合約檢測實驗室帶來了對先進液相層析質譜儀 (LC-MS) 基礎設施的強勁且持續的需求。
本報告考察了全球質譜市場,提供了市場概述、影響市場成長的各種因素分析、技術和專利趨勢、法律制度、案例研究、歷史和預測市場規模、按各個細分市場和地區/主要國家進行的詳細分析、競爭格局以及主要公司的概況。
The global mass spectrometry market is projected to reach USD 10,783.3 million by 2031 from USD 7,074.0 million in 2026, at a CAGR of 8.8% from 2026 to 2031.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Product, Inlet Type, Application, End User, and Region |
| Regions covered | North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa |
The global mass spectrometry market is experiencing strong growth driven by the rapid expansion of precision medicine, biologics development, multi-omics research, and regulatory-driven bioanalytical testing across pharmaceutical, biotechnology, clinical diagnostics, food safety, and environmental sectors. One of the latest trends accelerating market growth is the increasing adoption of high-resolution LC-MS/MS and hybrid mass spectrometry platforms integrated with AI-enabled analytics, automation, cloud-connected laboratory workflows, and robotic sample preparation to improve throughput, reproducibility, and operational efficiency.

Pharmaceutical and biopharmaceutical companies are heavily investing in advanced mass spectrometry systems for biomarker discovery, antibody-drug conjugate (ADC) characterization, cell and gene therapy development, and FDA-compliant pharmacokinetic analysis, while hospitals and diagnostic laboratories are increasingly deploying benchtop clinical LC-MS/MS systems for endocrinology, toxicology, and precision oncology testing. Additionally, the rapid growth of outsourced bioanalytical services through CROs, increasing PFAS and environmental contaminant testing, and the transition toward digitally integrated and standardized analytical ecosystems are further strengthening global demand for next-generation hybrid and high-throughput mass spectrometry platforms.
The instruments segment accounted for the largest share of the mass spectrometry market.
By product, the mass spectrometry market is segmented into instruments, software, and services. During the forecast period, the instruments segment is projected to hold the largest share of the mass spectrometry market owing to increasing investments in advanced analytical technologies across pharmaceutical, biotechnology, clinical research, and multi-omics applications. The growing demand for high-performance mass spectrometry instruments is being driven by the rising complexity of drug development workflows involving biologics, antibody-drug conjugates (ADCs), cell and gene therapies, and precision medicine initiatives. Pharmaceutical and biopharmaceutical companies are increasingly investing in next-generation mass spectrometry platforms with improved sensitivity, high-resolution analysis, automation, and AI-enabled workflow capabilities to enhance bioanalytical efficiency, accelerate research timelines, and ensure regulatory compliance. Furthermore, developed regions such as North America and Europe are witnessing faster instrument replacement and upgrade cycles due to continuous technological innovation and the increasing adoption of high-throughput analytical systems across research laboratories, hospitals, and clinical institutions.
"The LC-MS segment accounted for the largest share of the mass spectrometry market."
By inlet type, the mass spectrometry market is segmented into GC-MS, LC-MS, ICP-MS, and other inlet types. During the forecast period, the LC-MS segment is expected to dominate the global mass spectrometry market owing to its widespread adoption across pharmaceutical, biotechnology, clinical diagnostics, food safety, and environmental testing applications. LC-MS is one of the most extensively utilized analytical techniques for the identification and quantification of complex biological and chemical compounds with high sensitivity and accuracy. The segment is witnessing significant growth due to increasing regulatory acceptance, expanding biologics and precision medicine research, and rising demand for advanced bioanalytical testing workflows. One of the major market trends driving LC-MS adoption is the implementation of ICH M10 bioanalytical method validation guidelines by the U.S. Food and Drug Administration and other international regulatory agencies, which recognize LC-MS/MS as the preferred technology for pharmacokinetic analysis, biomarker quantification, and regulated drug testing. This regulatory shift is encouraging pharmaceutical companies and contract research organizations to increase investments in next-generation LC-MS/MS platforms to support clinical development, regulatory compliance, and high-throughput drug analysis applications.
"The pharma/biopharma manufacturing application segment accounted for the largest share of the mass spectrometry market."
The pharmaceutical and biopharmaceutical sectors are emerging as major application areas and key news trends in the mass spectrometry market due to the growing demand for advanced analytical technologies in drug discovery, biologics characterization, biomarker identification, and GMP-compliant quality control. Pharmaceutical companies are increasingly adopting LC-MS/MS and high-resolution mass spectrometry systems to support complex biologics, antibody-drug conjugates, peptides, cell and gene therapies, and biosimilar development, where traditional analytical methods are often insufficient. The rising focus on precision medicine, regulatory compliance, impurity profiling, and real-time process monitoring is further accelerating the adoption of advanced mass spectrometry platforms across pharmaceutical R&D and manufacturing operations.
In addition, the rapid expansion of omics research, proteomics, metabolomics, and personalized medicine is driving continuous innovation and product launches in the mass spectrometry industry. Leading companies are introducing automated, high-throughput, and AI-enabled mass spectrometry solutions to support translational research and biopharma workflows. The increasing outsourcing of bioanalytical testing to CROs and CDMOs, along with growing investments in biologics and advanced therapies, is further strengthening the role of mass spectrometry in pharmaceutical and biotechnology applications. These trends are positioning pharma and biopharma as the fastest-growing and highest-revenue-generating application segments within the global mass spectrometry market.
By end-user, the pharmaceutical companies segment is projected to account for the largest market share during the forecast period.
By end user, the mass spectrometry market is segmented into pharmaceutical companies, biotechnology companies, research laboratories & academic institutes, environmental testing laboratories, food & beverage industry, hospital clinical & forensic laboratories, petrochemical industry, and other end users. During the forecast period, the pharmaceutical companies segment is expected to register the fastest growth owing to the increasing adoption of advanced analytical technologies in biologics development, precision therapeutics, and multi-omics-based drug discovery workflows. One of the major trends driving growth in this segment is the rising deployment of advanced hybrid mass spectrometry platforms such as Orbitrap, Q-TOF, Triple Quadrupole Linear Ion Trap, and FT-MS systems for complex biologic characterization, antibody-drug conjugate (ADC) analysis, host-cell protein monitoring, and real-time process analytical technology (PAT) applications. Pharmaceutical and biopharmaceutical manufacturers are increasingly integrating high-resolution hybrid MS systems into manufacturing, quality control, and bioanalytical environments to support continuous bioprocessing, impurity profiling, glycosylation studies, and ultra-trace contaminant detection. This trend is particularly prominent in monoclonal antibody, mRNA, and cell therapy manufacturing facilities, where next-generation therapeutics require highly sensitive and high-resolution analytical capabilities beyond conventional testing technologies.
"Asia Pacific is projected to show the highest growth rate in the mass spectrometry market."
The mass spectrometry market spans five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia-Pacific mass spectrometry market is witnessing rapid transformation driven by the expansion of biologics manufacturing, multi-omics research, precision medicine programs, and large-scale pharmaceutical outsourcing across China, India, Japan, South Korea, and Southeast Asia. One of the latest trends is the increasing deployment of high-resolution hybrid LC-MS/MS, Orbitrap, and Q-TOF systems in CROs, CDMOs, and biopharmaceutical manufacturing facilities for advanced biologic characterization, impurity profiling, glycan analysis, and cell & gene therapy workflows. Governments across the region are heavily investing in genomics, proteomics, metabolomics, and translational medicine initiatives, accelerating the adoption of AI-enabled and cloud-connected mass spectrometry platforms in both research and clinical diagnostics environments. Another major trend reshaping the region is the rapid digitalization of analytical laboratories through robotic sample preparation, laboratory information system (LIS) integration, and automated bioanalytical workflows to support high-throughput drug development and regulatory compliance. Additionally, APAC is emerging as a global pharmaceutical and bioanalytical outsourcing hub, creating strong recurring demand for advanced LC-MS infrastructure among CROs and contract testing laboratories.
The major players in the mass spectrometry market include Thermo Fisher Scientific (US), Agilent Technologies (US), Sciex (US), Waters Corporation (US), Bruker (US), Shimadzu Corporation (Japan), and PerkinElmer Inc. (US), among others.
Research Coverage
The research report examines the mass spectrometry market by product, inlet type, application, end users, and region. This research covers factors that are driving market expansion, analyzes prospects and parameters faced by industries in the present time, and provides specifics on the competitive landscape, considering market leaders and small and medium enterprises. This research also estimates the revenue of different market segments by considering five regions and micro-market analysis.
Reasons to Buy the Report
The report will provide market leaders and new entrants with valuable information regarding the revenue estimates for the overall mass spectrometry market and its subsegments. It will help stakeholders understand the competitive landscape, allowing them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into the market dynamics, including key drivers, restraints, challenges, and opportunities.
16.3 GROWTH FORECASTING MODEL